Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results , with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ ...

We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning ...

Incyte Corporation INCY reported fourth-quarter 2024 adjusted earnings of $1.43 per share, which missed the Zacks Consensus Estimate of $1.53. The company had recorded earnings of $1.06 per share in ...

Incyte (INCY) reported $1.22 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 16.5%. EPS of $1.57 for the same period compares to -$1.82 a year ago. The ...

Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below ...

Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation ...

Incyte (INCY) came out with quarterly earnings of $2.26 per share, beating the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.07 per share a year ago. These figures are ...